Supernus Pharmaceuticals (NASDAQ: SUPN) is a specialty pharmaceutical company that develops and commercializes prescription drugs focused on central nervous system (CNS) disorders. Revenue comes from net product sales of branded drugs sold through the U.S. market, subject to significant rebate and returns activity. The company acquired Sage Therapeutics, Inc. during FY2025, expanding its CNS portfolio. Marketed products include Trokendi XR and Oxtellar XR for epilepsy, XADAGO for Parkinson's disease, and MYOBLOC for cervical dystonia and chronic sialorrhea. Pipeline assets include SPN-817, a novel anticonvulsant in clinical development, and SPN-820, being studied as an adjunctive treatment for major depressive disorder. Net revenues for FY2025 increased versus FY2024, though the company reported a net loss of $38.6 million for the year ended December 31, 2025, compared to net earnings of $73.9 million for the year ended December 31, 2024, driven primarily by higher intangible asset amortization and selling, general, and administrative expenses following the Sage acquisition.

Revenue model

Transactional prescription drug sales. Net product revenue is reduced by accrued product returns, rebates (including Medicaid and managed care rebates), and sales discounts. Total accrued product returns and rebates balance was $174.6 million as of December 31, 2025 (versus $181.1 million as of December 31, 2024), reflecting the scale of gross-to-net adjustments on branded drug sales.

Products and services

Oxtellar XR (oxcarbazepine): once-daily extended-release treatment for partial onset seizures in patients 6 years and older. Trokendi XR: extended-release topiramate for epilepsy and migraine prevention. XADAGO (safinamide): once-daily adjunctive treatment for Parkinson's disease patients experiencing OFF episodes. MYOBLOC (rimabotulinumtoxinB injection): the only botulinum toxin type B on the U.S. market, indicated for cervical dystonia and chronic sialorrhea in adults. Pipeline includes SPN-817 (novel synthetic huperzine A anticonvulsant, clinical stage) and SPN-820 (adjunctive MDD treatment, Phase 2b).

Customers and end markets

Patients and prescribers in the U.S. CNS specialty market, including neurology and psychiatry. End markets include epilepsy, Parkinson's disease, cervical dystonia, chronic sialorrhea, and major depressive disorder. Payers include Medicare, Medicaid, and commercial insurers. The Sage acquisition added contingent consideration tied to regulatory and commercial milestones in Japan, indicating an early-stage international end market for certain assets.

Value-chain role

Branded pharmaceutical developer and commercial-stage marketer. The company holds proprietary drug formulations and regulatory approvals, manufactures or contracts manufacturing of finished drug products, and sells through specialty pharmacy and wholesale distribution channels in the U.S. Subject to federal Anti-Kickback Statute, False Claims Act, FDA marketing restrictions, and Medicaid rebate obligations.

Geographic exposure

Primarily United States commercial operations. Japan identified as a development-stage market tied to contingent milestone payments from the Sage acquisition (regulatory approval and first commercial sale milestones outstanding as of December 31, 2025).

Competitors

Botox (AbbVie), Dysport (Ipsen), Xeomin (Merz), Generic baclofen, Generic anticholinergics, Generic benzodiazepines, Generic tetrabenazine

Source: SEC 10-K, filed 2026-03-02

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals Inc Axsome Therapeutics Inc Filana Therapeutics Inc Johnson & Johnson Revance Therapeutics, Inc. Tilray Brands Inc Ventyx Biosciences, Inc.